- Home
- PMVP vs ARTV Comparison
PMVP vs ARTV Comparison
Compare PMVP & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- ARTV
- Stock Information
- Founded
- PMVP 2013
- ARTV 2019
- Country
- PMVP United States
- ARTV United States
- Employees
- PMVP N/A
- ARTV N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- ARTV
- Sector
- PMVP Health Care
- ARTV
- Exchange
- PMVP Nasdaq
- ARTV NYSE
- Market Cap
- PMVP 71.9M
- ARTV 61.9M
- IPO Year
- PMVP 2020
- ARTV 2024
- Fundamental
- Price
- PMVP $0.88
- ARTV $1.94
- Analyst Decision
- PMVP Strong Buy
- ARTV Strong Buy
- Analyst Count
- PMVP 1
- ARTV 7
- Target Price
- PMVP $5.00
- ARTV $19.17
- AVG Volume (30 Days)
- PMVP 313.5K
- ARTV 141.2K
- Earning Date
- PMVP 05-09-2025
- ARTV 05-08-2025
- Dividend Yield
- PMVP N/A
- ARTV N/A
- EPS Growth
- PMVP N/A
- ARTV N/A
- EPS
- PMVP N/A
- ARTV N/A
- Revenue
- PMVP N/A
- ARTV N/A
- Revenue This Year
- PMVP N/A
- ARTV N/A
- Revenue Next Year
- PMVP N/A
- ARTV N/A
- P/E Ratio
- PMVP N/A
- ARTV N/A
- Revenue Growth
- PMVP N/A
- ARTV N/A
- 52 Week Low
- PMVP $0.81
- ARTV $1.78
- 52 Week High
- PMVP $1.85
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- PMVP 39.59
- ARTV N/A
- Support Level
- PMVP $0.87
- ARTV N/A
- Resistance Level
- PMVP $0.94
- ARTV N/A
- Average True Range (ATR)
- PMVP 0.06
- ARTV 0.00
- MACD
- PMVP 0.01
- ARTV 0.00
- Stochastic Oscillator
- PMVP 50.38
- ARTV 0.00
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).